Skip to main content

Table 2 Multivariate adjusted risk estimation of different systolic and diastolic blood pressure as well as pulse pressure quartiles for Cardiovascular disease in the total population and those with and without anti-hypertensive medication: Tehran Lipid and Glucose study (1999–2014)

From: Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study

 

BP category

Model 1

Model 2

 

E/N

HR

(95% CI)

p

HR

(95% CI)

P

Total (N = 1232)

SBP < 120

61/367

0.92

(0.63–1.34)

0.67

0.94

(0.64–1.38)

0.75

120 ≤ SBP < 130*

49/224

Ref

  

Ref

  

130 ≤ SBP < 140

42/211

0.95

(0.63–1.44)

0.81

0.87

(0.57–1.32)

0.52

SBP ≥ 140

165/430

1.67

(1.21–2.3)

0.002

1.68

(1.2–2.34)

0.002

Treated (N = 286)

SBP < 120

10/36

1.32

(0.5–3.5)

0.57

1.39

(0.51–3.8)

0.52

120 ≤ SBP < 130*

7/27

Ref

  

Ref

  

130 ≤ SBP < 140

12/48

1.19

(0.46–3.04)

0.71

1.09

(0.42–2.87)

0.85

SBP ≥ 140

66/175

1.69

(0.77–3.69)

0.19

2.01

(0.89–4.57)

0.1

Untreated (N = 946)

SBP < 120

51/331

0.87

(0.58–1.31)

0.51

0.9

(0.59–1.36)

0.61

120 ≤ SBP < 130*

42/197

Ref

  

Ref

  

130 ≤ SBP < 140

30/163

0.85

(0.53–1.36)

0.5

0.8

(0.5–1.29)

0.37

SBP ≥ 140

99/255

1.62

(1.12–2.34)

0.01

1.64

(1.13–2.39)

0.009

Total (N = 1232)

DBP < 80

132/544

1.61

(1.13–2.32)

0.009

1.55

(1.08–2.24)

0.02

80 ≤ DBP < 85*

38/242

Ref

  

Ref

  

85 ≤ DBP < 90

45/165

1.88

(1.22–2.90)

0.004

1.93

(1.25–2.98)

0.003

DBP ≥ 90

102/281

2.68

(1.85–3.89)

<0.001

2.63

(1.8–3.83)

<0.001

Treated (N = 286)

DBP < 80

24/77

2.13

(0.95–4.78)

0.065

2.00

(0.89–4.54)

0.09

80 ≤ DBP < 85*

8/55

Ref

  

Ref

  

85 ≤ DBP < 90

11/38

2.1

(0.84–5.22)

0.11

1.96

(0.77–4.95)

0.16

DBP ≥ 90

52/116

4.02

(1.9–4.85)

< 0.001

4.54

(2.13–9.67)

<0.001

Untreated (N = 946)

DBP < 80

108/467

1.5

(1.0–2.25)

0.049

1.43

(0.95–2.16)

0.09

80 ≤ DBP < 85*

30/187

Ref

  

Ref

  

85 ≤ DBP < 90

34/127

1.84

(1.13–3.01)

0.015

1.94

(1.19–3.18)

0.008

DBP ≥ 90

50/165

2.09

(1.33–3.29)

0.001

1.95

(1.23–3.08)

0.004

Total (N = 1232)

PP < 40*

46/327

Ref

  

Ref

  

40 ≤ PP < 50

70/291

1.5

(1.03–2.19)

0.034

1.44

(0.98–2.1)

0.06

50 ≤ PP < 64

79/307

1.43

(0.98–2.08)

0.06

1.28

(0.88–1.87)

0.2

PP ≥ 64

122/307

2.13

(1.48–3.06)

<0.001

1.92

(1.33–2.78)

0.001

Treated (N = 286)

PP < 40*

12/37

Ref

  

Ref

  

40 ≤ PP < 50

12/42

0.93

(0.42–2.09)

0.87

1.08

(0.47–2.50)

0.86

50 ≤ PP < 64

26/83

0.95

(0.47–1.93)

0.9

1.04

(0.51–2.13)

0.91

PP ≥ 64

45/124

1.06

(0.55–2.06)

0.86

1.16

(0.59–2.27)

0.66

Untreated (N = 946)

PP < 40*

34/290

Ref

  

Ref

  

40 ≤ PP < 50

58/249

1.67

(1.09–2.57)

0.019

1.52

(0.98–2.36)

0.058

50 ≤ PP < 64

53/224

1.5

(0.96–2.34)

0.075

1.31

(0.84–2.06)

0.24

PP ≥ 64

77/183

2.54

(1.65–3.91)

<0.001

2.34

(1.51–3.63)

< 0.001

  1. Age was adjusted by considering it as the time-scale
  2. Model 1: Adjusted for sex
  3. Model 2: Adjusted for sex, BMI, diabetes, hypercholesterolemia, eGFR, smoking and anti-hypertensive medication (only for total population)
  4. BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, pp pulse pressure, E/N events/N, HR hazard ratio, CI confidence interval
  5. *Reference intervals